12.2 Kava and kavalactones (p.68)
[... Discussion of kava and background of consideration for scheduling ...]
Schedule 4 - New entry (p.71)
PIPER METHYSTICUM (Kava) in preparations for human use except:
(a) in preparations for oral use containing dried whole or peeled rhizomes or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome when labelled with a recommended daily dose of 250mg or less of kavalactones:
... (i) containing more than 25mg of kavalactones per dose, labelled with the statement: "WARNING: Not for prolonged use. Not recommended for use by pregnant or lactating women. May harm the liver";
... (ii) in tablet or capsule form containing 125mg or less of kavalactones per tablet or capsule; or
... (iii) in the form of a teabag when the amount of dried whole or peeled rhizome does not exceed 3g;
(b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome; or
(c) in dermal preparations.